THINQ NUTRACEUTICAL DIVISION PRESENTS.....



THINQURE 20

A Clinically proven Herbal Composition for assisting in early recovery from Covid infection by reducing Viral Load.



Helps To Reduce Viral Load In Mild & Moderate Viral Infections by Reducing Viral Load



THINQURE20

- Ingredients- Piper longum, Piper nigrum, Zingiber officinale, rock salt.....(Patent filed)
- Dosage form -500 mg ODT ..
- **Special instruction** Do not swallow or crush. Chew till it completed disintegrate in saliva.
- Drug Administration time Composition should be given as '4 hrly with with regular intervals. 1 Tablet 4 times a day

SALIENT FEATURES OF THE COMPOSITION



- Poly-herbal proprietary formulation. FDA license for the same.
- All ingredients are Indian spices and well endorsed as having immunity boosting activity.
- Also effective to control viral growth at Nasopharyngeal level
- •To reduce chance of +ve patients to get in to full blown SARS COV-2(Pneumonia) disease condition.



EFFICACY - RT-qPCR - RUO QUANTITATIVE COVID-19 (SARS-COV-2) TESTING BY REAL-TIME PCR

RT-qPCR-'Quantification of viral load'.

- Viral load Is inversion ally proportional to CT value
- Viral load is directly proportional to Disease severity

Viral load is equally important as any other marker like CRp , D Dimer etc

SAMPLE REPORT - RTQPCR



GenePath Dx

Above Phadke Hospital, 1260/B Jangli Maharaj Road, Shivajinagar, Pune 411004 Mobile: +91 96234 95511 | Telefax: +91 20 2553 4780

contactus@genepathdx.com | www.genepathdx.com

LAB REPORT

Sample Initials: P_H (I) Sample Code: 20604A

Sample Type: Combined NP+OP swab in VTM

Referred by: Quest / YCM

GenePath Code: QST011

Accessioned: Aug 12, 2020 Reported: Aug 16, 2020

RUO QUANTITATIVE COVID-19 (SARS-COV-2) TESTING BY REAL-TIME PCR

Tests requested: Quantitative RT-qPCR for SARS-CoV-2 (Covid-19) RNA from the provided sample.

Test performed: Viral nucleic acids were extracted from the provided sample. A multiplexed real-time PCR test (dual labelled probe chemistry) for SARS-CoV-2 was carried out on the extracted nucleic acids along with quantitative standards and negative controls using an ICMR approved real-Time RT-PCR Covid-19 diagnostic kit.

Results:

	Human Gene Control	RDRP		N		E		Final	
Sample / Standard	Ct*	Ct*	Calculated concentration (copies/ul)	Ct*	Calculated concentration (copies/uL)	Ct*	Calculated concentration (copies/uL)	Average concentration (copies/uL) in the reaction tube*	Final concentration (copies/mL) in the VTM tube^
5000 copies/uL	NA	24.52	5000	24.11	5000.00	25.32	5000.00	5000.00	NA
50 copies/uL	NA	31.37	50.00	31.16	50.00	32.29	50.00	50.00	NA
Sample	23.43	20.99	53657.07*2	20.27	61423.10*2	21.77	52194.09*2	55758.09*2	27879043

[&]quot;The PCR amplification cycle threshold (Ct) value is only reported when amplification is seen for that target. Ct values vary inversely with the logarithmic concentrations of nucleic acid targets in the sample i.e. a low Ct value is indicative of a high target concentration. Ct values can vary due to a number of factors including, but not limited to, the

Viral Load



Tab THINQURE20

1. Safety

2. Efficacy

3. Pharmacodynamics (How formula works)

SAFETY FIRST



▶ This formulation is referred in Ayurvedic textbooks accepted by Ministry Of Ayush. Such textual compositions are safe and directly can go for Phase IV / PMS studies.

▶ Individual as well as combined ingredients are in use since last three thousand years.

INVIVO HUMAN STUDY



Study Title - A Non-interventional, Retrospective, Observational study to analyze safety, efficacy and tolerability of THINQURE 20 in COVID-19 patients"

- ► CTRI Num CTRI/2021/03/032471
- Study: done for 30 patients Primary end point to check viral load pre and post treatment

Outcome -

- Decline in Viral Load was observed to be more than 70% for 22 patients
- Decline in Viral Load was observed to be more than 70% for 6 patients


IMPORTANCE OF <u>VIRAL LOAD</u> IN CLINICAL EFFICACY

- https://www.businesswire.com/news/home/20210315005197/en/UK-Clinical-Trial-Confirms-SaNOtize%E2%80%99s-Breakthrough-Treatment-for-COVID-19
- UK Clinical Trial Confirms SaNOtize's Breakthrough Treatment for COVID-19
- Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours

It Confirms

- ► Importance of Viral Load in Clinical Efficacy
- Acceptance of Naso-pharayngeal root in administration of drug for Covi19 infection

THE TREATMENT WITH THINQURE 20 FOR 5 DAYS SIGNIFICANTLY (P<0.001) REDUCED THE VIRAL LOAD IN THE COVID 19 PATIENTS WHEN COMPARED WITH VIRAL LOAD BEFORE TREATMENT.



Viral load from in COVID-19 patients Pre & Post Treatment

PTS	Pre Rx	Post Rx	Differece	Decline %
1	29.9	0.3	29.6	98.8
2	93.8	1.3	92.5	98.6
3	666.0	0.4	665.6	99.9
4	6350.0	0.8	6349.2	100.0
5	852.0	3.8	848.2	99.6
6	0.6	0.1	0.5	78.9
7	0.1	0.0	0.0	59 .%
8	15.5	3.4	12.1	78.3
9	27.0	0.1	26.9	99.7
10	171.0	0.7	170.3	99.6
11	248.0	4.0	244.0	98.4
12	76.4	4.8	71.6	93.8
13	11.5	0.3	11.2	97.6
14	0.3	0.1	0.2	73.9
15	1.3	0.1	1.2	95.9
16	84500.0	30300.0	54200.0	64.1
1 <i>7</i>	278.8	14.9	263.8	94.6
18	0.5	0.0	0.5	97.3
19	30.1	0.1	30.0	99.7
20	1690.6	108.7	1581.9	93.6
21	4419.4	256.0	4163.4	94.2
22	67.7	15.5	52.2	77.1




PHARMACODYNAMICS

		PHARMACODYNAMIC ACTIVITY OF FORMU	LATION
		Pharmacological Hypothesis.	
1		ACEII Receptor blockers	Prophylaxis
		Zingiber officinale - https://pubmed.ncbi.nlm.nih.gov/24433069/	
	Herbs 2	Molecular Docking - Antiviral activity of selected phytochemicals against SARS-CoV-2 and its cellular receptor	
2		(Spike Glycoprotein of covid against Piperine, & Zingiberenece Gingerol) https://link.springer.com/article/10.1007/s13337-020-00598-8	Antivirol 12

COVID 19 & ACE II RECEPTORS



ACE II receptors - Entry gates for Covid. Max in Nasal passage, throat mucosa.



ACE II receptors are maximum in Nose & Oral mucosa. By inhaling phytochemicals like **Zigiberene** (**Ginger**) and **Eugenol**(**Clove**) can block them and avoid entry of viruses in Human Body

https://www.youtube.com/watch?v=iBz5kfLlynY

IN-VITRO STUDIES..... CONTINUE




(Done from NABL accredited)

- Antiviral activity against <u>Human Coronavirus HCoV-</u>
 229E 97.76%
- 2. Antiviral activity against envelope virus **INFLUENZA** (H3N2)- 99.92%
- 3. Antiviral activity against Non- envelope virus (Bacteriophage) MS2 85%
- 4. 3. Antifungal activity against one of the MUCOR species IE <u>Mucor racemosus</u> 96.15%

Thank you!!

IN-VITRO STUDIES- THINQURE20 – PROPHYLAXIS FOR COVID INFECTION



▶ **RESULT** - Thinqure 20 extract showed anti SARS-CoV-2 Spike-ACZZ inhibition activity when tested invitro at higher concentrations of 0.125mg/ml the inhibitory percentage was found to be 22,69% till 1.0mg/ml where 78.46% of the reaction was inhibited (p<0.01 using One-Way ANOVA). The kit-based SARS inhibitor showed 89.00% inhibition when used as per KIT's instructions.

15

IN-VITRO STUDIES.....ACE II RECEPTOR **BLOCKING ACTIVITY OF THINQURE20**

Name of Kit – SARS-COVID 2- SPIKE-ACE INTERACTION INHIBITOR SCREENING KIT (CAYMENY CHEMICAL)

RESULT

Sr NUm	Conc/Mg/ MI	Thinqure20 (In %)	Inhaler (In %)
1	0.125	22.69	17.69
2	0.5	70.06	30.77
3	1.00	78.46	40.77

CONCLUSION - Thinqure 20 is having excellent prophylaxis activity against SARS Covid19 virus as its blocking entry through ACEII receptor.